Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

NCT02317471 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Gastric Carcinoma

Interventions

BIOLOGICAL: autologous gp96 vaccination
DRUG: Oxaliplatin+S-1

Sponsor

Chinese PLA General Hospital

Collaborators

[object Object]